DNA diangnosis of lateral lymph nodes of rectum by HOPX methylation

结直肠癌的DNA诊断目前面临着发展微小残留癌的挑战。HOPX甲基化可以在1/500的癌细胞中检测到，然而，这不足以检测微小残留疾病。为了提高敏感性，必须开发更好的标记，提高DNA质量或其他技术。我们还没有质疑巢式PCR可能有希望用于此目的（DNA短缺使我们无法继续进行此实验）。CDO-1是这样的候选物，然而即使是这种新的候选物也仅在CRC患者的血浆中检测到至多20%，并且在转移性淋巴结中几乎没有发现。仍在进行进一步挑战，以检测微小残留病。

DNA diagnosis of colorectal cancer is now challenging to develop minimal residual disease of cancer. HOPX methylation could be detected in 1/500 of cancer cells, and, however, this would not be enough to detect minimal residual disease. In order to increase the sensitivity, exploration of better markers, improvement of DNA quality or other technology must be developed. We have not yet challenged the nested PCR may be promising for this purpose(DNA shortage makes us failure to continue this experminets). CDO-1 was such candidates, however even this novel candidates were only to detect at most 20% in plasma of CRC patients, and hardly found in metastatic lymph nodes. Still ongoing for further challenge to detect the minimal residual disease.